Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma

Additional Metadata
Keywords	Escalated dose, First relapse, Multiple myeloma, VRD
Persistent URL	doi.org/10.3324/haematol.2015.132431, hdl.handle.net/1765/91962
Journal	Haematologica
Organisation	Erasmus MC: University Medical Center Rotterdam
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Broijl, A., Kersten, M. J., Alemayehu, W. G., Levin, M.-D., de Weerdt, O., Vellenga, E., … Sonneveld, P. (2016). Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma. Haematologica, 101(4), e149–e152. doi:10.3324/haematol.2015.132431

Publication